Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG0302-COVID19 intramuscular or intradermal dose-schedule safety and immunogenicity study
jRCT2051210052Phase 2Completed
- Sponsor
- AnGes, Inc.
- Start
- Jul 2021
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AG0302 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by AnGes, Inc. Primary endpoints: Incidence of treatment-emergent adverse events, Neutralizing activity against SARS-CoV-2 pseudovirus and 1 more. Started Jul 2021; status: completed.
02
Drugs
AG0302
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051210052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210052.